CredoScientia - Bibliothèque

Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report.

BACKGROUND: The treatment of gastric cancer remains highly challenging, particularly in cases of unresectable locally advanced or metastatic disease. Although chemotherapy and immunotherapy have shown…

Thérapies de Conversion

Du, X. Y., Xia, R. J., Shen, L. W., Ma, J. G., Yao, W. Q., Xu, W., Lin, Z. P., Ma, L. B., Niu, G. Q., Fan, R. F., Xu, S. M., & Yan, L. (2025). Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report.. World J Gastrointest Oncol, 17(4), 102258. https://doi.org/10.4251/wjgo.v17.i4.102258

15/04/2025 Lire →

Radiologic complete response after conversion therapy for hepatocellular carcinoma: is liver transplantation necessary?

Thérapies de Conversion

Gao, C. H., Cao, L. P., Cheng, S. Q., Wang, L., Wang, J. Z., Yan, M. L., Zheng, S. S., & Yang, Z. (2025). Radiologic complete response after conversion therapy for hepatocellular carcinoma: is liver transplantation necessary?. Hepatobiliary Surg Nutr, 14(2), 351-354. https://doi.org/10.21037/hbsn-2024-702

01/04/2025 Lire →

Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.

Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conve…

Thérapies de Conversion

Bi, X., Zhao, H., Zhao, H., Li, G., Wang, X., Chen, B., Zhang, W., Che, X., Huang, Z., Han, Y., Jiang, L., Sun, Y., Yang, Z., Zhou, J., Zhang, Y., Zhu, Z., Chen, M., Cheng, S., & Cai, J. (2025). Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update.. Liver Cancer, 14(2), 223-238. https://doi.org/10.1159/000541249

01/04/2025 Lire →

Predictive Biomarkers for the Efficacy of Conversion Therapy in Gastric Cancer are Expected to be a Prominent Research Focus.

Thérapies de Conversion

Ye, Y. X., Chen, S. R., Wu, C. Y., & Ye, K. (2025). Predictive Biomarkers for the Efficacy of Conversion Therapy in Gastric Cancer are Expected to be a Prominent Research Focus.. Ann Surg Oncol, 32(4), 2673-2674. https://doi.org/10.1245/s10434-024-16710-x

01/04/2025 Lire →

Synchronous metastatic malignancy of the prostate and stomach: A case report.

INTRODUCTION: Gastric cancers are silent malignancies that are typically diagnosed at advanced stages. Similarly, patients with prostate cancer can have an asymptomatic presentation despite widespread…

Thérapies de Conversion

Nanda, A. K., Walcott, A., Goodnough, M., Bernardez-Lai, S., & Villamil, S. (2025). Synchronous metastatic malignancy of the prostate and stomach: A case report.. Int J Surg Case Rep, 129, 111179. https://doi.org/10.1016/j.ijscr.2025.111179

01/04/2025 Lire →

Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.

Gastric cancer with peritoneal dissemination remains a significant clinical challenge due to its poor prognosis and difficulty in early detection. This study introduces a multimodal artificial intelli…

Thérapies de Conversion

Ding, P., Yang, J., Guo, H., Wu, J., Wu, H., Li, T., Gu, R., Zhang, L., He, J., Yang, P., Tian, Y., Meng, N., Li, X., Guo, Z., Meng, L., & Zhao, Q. (2025). Multimodal Artificial Intelligence-Based Virtual Biopsy for Diagnosing Abdominal Lavage Cytology-Positive Gastric Cancer.. Adv Sci (Weinh), 12(15), e2411490. https://doi.org/10.1002/advs.202411490

01/04/2025 Lire →

Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma.

Thérapies de Conversion

Ning, J., Dai, C., Liu, Q., Lin, H., & Zhang, R. (2025). Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma.. Br J Surg, 112(4). https://doi.org/10.1093/bjs/znaf067

28/03/2025 Lire →

Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report.

BACKGROUND: Hepatocellular carcinoma (HCC) is a prevalent malignancy in China, primarily diagnosed at advanced stages, which limits treatment options and increases mortality rates. Conversion therapy,…

Thérapies de Conversion

Wang, C. D., Liu, R. D., Liu, M. J., & Song, J. (2025). Lung metastasis following temporary discontinuation of lenvatinib and tislelizumab in hepatocellular carcinoma: A case report.. World J Gastrointest Surg, 17(3), 100951. https://doi.org/10.4240/wjgs.v17.i3.100951

27/03/2025 Lire →

Circulating Tumor DNA Predicts Conversion Therapy Response and Prognosis in Initially Unresectable Colorectal Liver-Limited Metastases: A Retrospective Study.

Effective molecular biomarkers for predicting prognosis and guiding treatment in patients with initially unresectable colorectal liver metastases (CRLMs) undergoing conversion therapy are currently l…

Thérapies de Conversion

Han, B., Shen, C., Hu, H., Zhang, J., Xie, X., Mo, Q., & Deng, Y. (2025). Circulating Tumor DNA Predicts Conversion Therapy Response and Prognosis in Initially Unresectable Colorectal Liver-Limited Metastases: A Retrospective Study.. Br J Hosp Med (Lond), 86(3), 1-16. https://doi.org/10.12968/hmed.2024.0695

26/03/2025 Lire →

[Surgical problems and considerations in conversion treatment of stage IV gastric cancer].

The prognosis of stage IV gastric cancer is extremely poor. Due to the diversificationof treatment methods and the rise and popularizationof multidisciplinary treatment(MDT), the conversion therapy fo…

Thérapies de Conversion

Shu, Y. J., Mei, J. W., & Dong, P. (2025). [Surgical problems and considerations in conversion treatment of stage IV gastric cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 28(3), 330-337. https://doi.org/10.3760/cma.j.cn441530-20240818-00289

25/03/2025 Lire →

Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma: A case report.

BACKGROUND: Hepatocellular carcinoma (HCC) has become a growing health concern globally. Microvascular invasion and high tumor burden are key factors limiting the curative effect of selective internal…

Thérapies de Conversion

Hao, M. Z., Lin, H. L., Hu, Y. B., Chen, Q. Z., Chen, Z. X., Qiu, L. B., Lin, D. Y., Zhang, H., Zheng, D. C., Fang, Z. T., & Liu, J. F. (2025). Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma: A case report.. World J Gastrointest Oncol, 17(3), 100861. https://doi.org/10.4251/wjgo.v17.i3.100861

15/03/2025 Lire →

Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular

BACKGROUND: Atezolizumab plus bevacizumab is recommended as a first-line treatment for unresectable hepatocellular carcinoma (uHCC). A subgroup analysis of the IMbrave150 trial showed shorter overall …

Thérapies de Conversion

Kodama, Y., Ueshima, K., Moriguchi, M., Inaba, Y., Yamashita, T., Iwamoto, H., Ueno, M., Ogasawara, S., Kuzuya, T., Kodama, T., Sato, Y., Tada, T., Tsuchiya, K., Nishiofuku, H., Yamakado, K., Sone, M., Ikeda, M., Takehara, T., Hamano, T., & Kudo, M. (2025). Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular . BMC Cancer, 25(1), 434. https://doi.org/10.1186/s12885-025-13648-5

11/03/2025 Lire →